Upcoming events on SEAGEN INC. |
|
07/28/22 | | Interim 2022 Earnings Release (Projected) |
10/27/22 | | Q3 2022 Earnings Release (Projected) |
02/09/23 | | FY 2022 Earnings Release (Projected) |
04/27/23 | | Q1 2023 Earnings Release (Projected) |
|
Past events on SEAGEN INC. |
|
06/10/22 | 05:30am | | European Hematology Association Meeting |
06/06/22 | 04:00pm | | American society of clinical oncology meeting - abstract number: 0000 |
06/06/22 | 02:15pm | | American society of clinical oncology meeting - abstract number: ps6100 |
06/06/22 | 11:12am | | American society of clinical oncology meeting - abstract number: 507 |
06/06/22 | 09:00am | | American society of clinical oncology meeting - abstract number: ps1127 |
06/06/22 | 09:00am | | American society of clinical oncology meeting - abstract number: ps1111 |
06/06/22 | 09:00am | | American society of clinical oncology meeting - abstract number: ps1108 |
06/05/22 | 09:00am | | American society of clinical oncology meeting - abstract number: ps3159 |
06/05/22 | 09:00am | | American society of clinical oncology meeting - abstract number: ps3154 |
06/05/22 | 09:00am | | American society of clinical oncology meeting - abstract number: ps3155 |
|
Past dividends on SEAGEN INC. |
|
- No events available -
|
|
Fiscal Period : December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
Sales M $ |
Released Forecast Spread | 482 482 0,00% | 655 644 1,7% | 917 846 8,4% | 2 176 2 160 0,71% | 1 574 1 546 1,8% | 1 787 |
Operating income (EBITDA) M $ |
Released Forecast Spread | -172 -199 14% | -234 -212 -10% | -197 -246 20% | 649 587 11% | -616 -605 -1,8% | -557 |
Operating profit (EBIT) M $ |
Released Forecast Spread | -196 -215 9,1% | -260 -237 -9,7% | -221 -266 17% | 597 587 1,7% | -682 -665 -2,5% | -657 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | -159 -128 -24% | -246 -170 -45% | -159 -261 39% | 616 608 1,3% | -676 -650 -3,9% | -658 |
Net income M $ |
Released Forecast Spread | -126 -129 3,0% | -223 -172 -29% | -159 -262 39% | 614 597 2,7% | -674 -639 -5,6% | -653 |
EPS $ |
Released Forecast Spread | -0,88 -0,90 2,3% | -1,41 -1,11 -27% | -0,96 -1,59 40% | 3,37 3,31 1,9% | -3,70 -3,50 -5,7% | -3,45 | Announcement Date | 02/06/2018 | 02/07/2019 | 02/06/2020 | 02/11/2021 | 02/09/2022 | - |
|
|
Fiscal Period : December | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
Sales M $ |
Released Forecast Spread | 235 208 13% | 278 257 8,2% | 1 062 487 118% | 601 587 2,5% | 332 336 -1,2% | 388 358 8,7% | 424 385 10% | 430 402 7,0% | 426 403 5,9% | 438 | 454 | 468 | 488 | 518 |
Operating income (EBITDA) M $ |
Released Forecast Spread | -106 -153 30% |
| 648 610 6,3% | 181
| -106 -114 6,7% | -79,6 -107 26% | -287 -93,0 -209% | -154 -112 -37% | -116 -160 28% | -116 | -129 | -141 | -24,8 | -28,2 |
Operating profit (EBIT) M $ |
Released Forecast Spread | -112 -130 13% | -94,0 -117 20% | 638 98,6 547% | 165 161 2,7% | -122 -114 -7,1% | -89,6 -113 21% | -298 -107 -179% | -172 -162 -6,5% | -133 -187 29% | -159 | -176 | -195 | -117 | -103 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | -168 -128 -31% | -21,2 -110 81% | 639 125 411% | 166 161 3,3% | -121 -109 -12% | -84,6 -110 23% | -293 -102 -187% | -177 -158 -12% | -135 -180 25% | -160 | -175 | -187 | -117 | -103 |
Net income M $ |
Released Forecast Spread | -168 -128 -32% | -21,2 -105 80% | 636 92,6 587% | 167 158 5,8% | -121 -109 -12% | -84,6 -109 22% | -294 -103 -185% | -175 -156 -12% | -136 -182 25% | -157 | -171 | -189 | -117 | -103 |
EPS $ |
Released Forecast Spread | -0,98 -0,75 -30% | -0,12 -0,60 80% | 3,50 0,24 1 379% | 0,90 0,86 5,0% | -0,67 -0,61 -9,1% | -0,47 -0,60 22% | -1,61 -0,57 -181% | -0,95 -0,84 -13% | -0,74 -1,00 26% | -0,84 | -0,92 | -1,01 | -0,69 | -0,61 | Announcement Date | 04/30/2020 | 07/30/2020 | 10/29/2020 | 02/11/2021 | 04/29/2021 | 07/29/2021 | 10/28/2021 | 02/09/2022 | 04/28/2022 | - | - | - | - | - | |
|
|
Upcoming sector events for SEAGEN INC. |
|
|
|
Past sector events for SEAGEN INC. |
|
|
|
|
|
|
Merck considering purchase of cancer drug maker Seagen - WSJ |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|